Company intelligence / Profile preview
NanoGroup S.A.
Warsaw, Mazowieckie, Polandnanogroup.eu ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
NanoGroup’s pipeline consists of pre-clinical programs focused on innovative nanomedicine solutions. These include polysaccharide nanoparticle-based drug carriers for oncology indications such as ovarian cancer and a suite of next-generation human/veterinary blood substitutes. No clinical results have been published yet as all programs are in early-stage development
- Therapeutic areas
- OncologyNephrologyHematology
- Modalities
- Polysaccharide nanoparticles (e.g., dextran-based carriers)nanotechnology-enabled drug delivery systemsblood substitutes
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Collaborations with leading research institutes in the US, China, Italy; no major pharma partnerships publicly listed yet
Beyond the preview
Go deeper on NanoGroup S.A..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NanoGroup S.A..